🔴 SLS is trading 4.3% down today as traders lock in profits after REGAL trial rally

SLS is trading at $14.12 (4.3% down) as the stock pulls back following a significant multi-day rally driven by Phase 3 REGAL trial optimism.

• The stock recently jumped more than 60% as investors anticipated final data from its lead clinical program.
• Current pre-market weakness reflects profit-taking and a normalization of volatility following the news-driven spike.
• Market focus remains on the upcoming REGAL trial results, which continue to serve as the primary catalyst for the biotech firm.